ViaCell (VIAC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ViaCell (VIAC)

VIAC 40.77

+3.6%

Dec 4 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Amy J	1/25/2005 10:06:43 PM
	of 9

Amgen Profits From Stem Cell IPO forbes.com Amgen (nasdaq: AMGN) bought 2.5 million shares of ViaCell in 2003 at $8 per share. In addition to developing stem cells as treatments for diseases--particularly as replacements for bone-marrow transplants to treat certain cancers--ViaCell also has a second business called ViaCord. Parents pay to bank their children's umbilical cord blood for future use.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next